+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 4
Age: 18Years +
FEMALE
ID07157423

Evaluating the Safety of Eptacog Alfa for Treating Severe Heavy Bleeding After Childbirth in India

Led by Novo Nordisk A/S · Updated on 2026-09-25

64

Participants Needed

14

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

This research aims to evaluate the safety of the medicine eptacog alfa in women in India who experience severe heavy bleeding after giving birth, known as severe postpartum haemorrhage PPH. The study focuses on women aged 18 years or older who have given birth after 27 weeks of pregnancy and have PPH that does not respond to standard uterotonic treatments. The goal is to gather more knowledge about how safe eptacog alfa is when used for this purpose. Participants will receive a single intravenous bolus injection of eptacog alfa NovoSeven to help stop the bleeding. If the first dose does not stop the bleeding, an additional dose may be given. This study is a Phase IV interventional trial conducted with a single treatment group and will last about 30 to 35 days for each participant. During the study, participants will be monitored for any thromboembolic events from the start of treatment through 30 days after. Researchers will also track serious adverse events, allergic reactions, and any medication errors at baseline and throughout the study period. The study involves careful observation and safety monitoring to understand the effects of eptacog alfa in these women.

CONDITIONS

Brief Title

A Research Study to See How Safe is Eptacog Alfa When Used to Stop Heavy Bleeding in Women After Giving Birth in India

Research Team

N

Novo Nordisk

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here